We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Prenatal Testing Can Detect Cancer in Mothers

By HospiMedica International staff writers
Posted on 26 Jul 2015
Print article
A new study suggests that noninvasive prenatal testing (NIPT) for genetic anomalies could identify occult, previously undiagnosed maternal malignancies.

Researchers at Tufts University Medical Center (Boston, MA, USA), the Dana-Farber Cancer Institute (Boston, MA, USA), and other institutions analyzed 125,426 samples submitted between February 15, 2012, and September 30, 2014, from asymptomatic pregnant women who underwent NIPT screening for fetal aneuploidy (chromosomes 13, 18, 21, X, and Y). Abnormal results were detected in 3,757 (3%) of samples; these were reported to the ordering physician with recommendations for further evaluation.

The results showed that from the set of 3,757 aneuploidy samples, 10 cases of maternal cancer were identified. Detailed clinical and sequencing data were obtained in eight of the women. The researchers found that maternal cancers most frequently occurred when an NIPT finding of more than one aneuploidy was detected. All eight cases that underwent further bioinformatics analysis showed unique patterns of nonspecific copy-number gains and losses across multiple chromosomes. In one case, blood was sampled after completion of treatment for colorectal cancer and the abnormal pattern was no longer evident. The study was published on July 14, 2015, in JAMA.

“If someone has cancer, the tumor itself is shedding DNA in the mother's blood. The test is picking up excess amounts of DNA from particular chromosomes. It's kind of an accident in a way that the test is picking up the DNA from the tumor,” said lead author medical geneticist Diana Bianchi, MD, executive director of the Mother Infant Research Institute at Tufts Medical Center. “The take-home message is that women should be aware of this possibility when they seek testing. It doesn't necessarily mean anything is wrong with the fetus.”

NIPT is a screening test that analyzes the mother's blood and contains fragments of both placental and maternal DNA. Certain fetal abnormalities are associated with specific chromosomes and may indicate birth defects or a condition such as Down's syndrome. NIPT can be done as early as the 10th week of pregnancy, and is typically offered to women with high-risk pregnancies, such as older mothers or those with a family history of certain birth defects.

Related Links:

Tufts University Medical Center
Dana-Farber Cancer Institute


Gold Member
12-Channel ECG
CM1200B
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Anesthesia Workstation
X40

Print article

Channels

Surgical Techniques

view channel
Image: LUMISIGHT and Lumicell DVS offer 84% diagnostic accuracy in detecting residual cancer (Photo courtesy of Lumicell)

Cutting-Edge Imaging Platform Detects Residual Breast Cancer Missed During Lumpectomy Surgery

Breast cancer is becoming increasingly common, with statistics indicating that 1 in 8 women will develop the disease in their lifetime. Lumpectomy remains the predominant surgical intervention for treating... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.